Oruka Therapeutics, Inc. (ORKA) is in Healthcare, Biotechnology, based in United States, listed on NasdaqGM. Market cap 5.12B USD. 52-week range 24.31 to 115.52 USD. Data as of 2026-10-09.
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. ...